Ubisol-Q10 (A Nanomicellar Water-Soluble Formulation of CoQ10) Supplementation Inhibits Behavioural and Pathological Symptoms in Double Transgenic Mouse Models of Alzheimer's Disease
Standing
Undergraduate
Type of Proposal
Oral Presentation
Faculty
Faculty of Science
Faculty Sponsor
Dr. Siyaram Pandey
Proposal
Culmone, L., Vegh, C., Wear, D., Huggard, R., Okaj, I., Pandey, S., Cohen, J. Alzheimer’s disease (AD) is the most common neurodegenerative disorder and is characterized by the progression of debilitating symptoms which affect the daily lives of those afflicted. Alzheimer’s disease has been heavily researched, however, researchers have yet to discover an effective treatment which halts its neurodegenerative progression and recent clinical trials have failed to provide promising results. Due to the rapidly aging global population, the prevalence of AD is increasing dramatically and, therefore, it is imperative that a treatment which reduces the progression of this disease is discovered. Although the molecular mechanisms of AD are not fully understood, mitochondrial dysfunction, oxidative stress, and the accumulation of dysfunctional proteins are known to be involved in its pathology. It has previously been demonstrated that a water-soluble formulation of Coenzyme Q10 (Ubisol-Q10), which is an integral part of the election transport chain, stabilizes mitochondria and prevents neuronal death by reducing the generation of free radicals. This has been displayed both in vitro and in vivo (Muthukumaran et al., 2014). In the present study, researchers report that providing Ubisol-Q10 (at a dose of ∼6 mg/kg/day) to transgenic mouse models of AD (TgAPEswe, PSEN1E9) reduced circulating amyloid-β peptide and amyloid-β plaques, increased microglia activation, and upregulated Beclin-1, which is a regulator of autophagosome formation. Additionally, the Ubisol-Q10 treated mice showed improved long-term memory and working spatial memory. Based on the results of the current study, it is evident that the Ubisol-Q10 supplementation has the potential to reduce the neurodegenerative progression that is characteristic of AD, which could lead to a better quality of life for individuals living with this disease.
Grand Challenges
Viable, Healthy and Safe Communities
Ubisol-Q10 (A Nanomicellar Water-Soluble Formulation of CoQ10) Supplementation Inhibits Behavioural and Pathological Symptoms in Double Transgenic Mouse Models of Alzheimer's Disease
Culmone, L., Vegh, C., Wear, D., Huggard, R., Okaj, I., Pandey, S., Cohen, J. Alzheimer’s disease (AD) is the most common neurodegenerative disorder and is characterized by the progression of debilitating symptoms which affect the daily lives of those afflicted. Alzheimer’s disease has been heavily researched, however, researchers have yet to discover an effective treatment which halts its neurodegenerative progression and recent clinical trials have failed to provide promising results. Due to the rapidly aging global population, the prevalence of AD is increasing dramatically and, therefore, it is imperative that a treatment which reduces the progression of this disease is discovered. Although the molecular mechanisms of AD are not fully understood, mitochondrial dysfunction, oxidative stress, and the accumulation of dysfunctional proteins are known to be involved in its pathology. It has previously been demonstrated that a water-soluble formulation of Coenzyme Q10 (Ubisol-Q10), which is an integral part of the election transport chain, stabilizes mitochondria and prevents neuronal death by reducing the generation of free radicals. This has been displayed both in vitro and in vivo (Muthukumaran et al., 2014). In the present study, researchers report that providing Ubisol-Q10 (at a dose of ∼6 mg/kg/day) to transgenic mouse models of AD (TgAPEswe, PSEN1E9) reduced circulating amyloid-β peptide and amyloid-β plaques, increased microglia activation, and upregulated Beclin-1, which is a regulator of autophagosome formation. Additionally, the Ubisol-Q10 treated mice showed improved long-term memory and working spatial memory. Based on the results of the current study, it is evident that the Ubisol-Q10 supplementation has the potential to reduce the neurodegenerative progression that is characteristic of AD, which could lead to a better quality of life for individuals living with this disease.